Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges

Meta-analysis: Statin Therapy Does Not Alter the Association Between Low Levels of High-Density Lipoprotein Cholesterol and Increased Cardiovascular Risk

(2013) Haseeb Jafri et al.   ANNALS OF INTERNAL MEDICINE

Anacetrapib and Dalcetrapib: Two Novel Cholesteryl Ester Transfer Protein Inhibitors

(2011) Marta A Miyares   ANNALS OF PHARMACOTHERAPY

Apolipoprotein A-I Therapy

(2011) Michael H. Davidson   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis

(2011) Amit V. Khera et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective

(2010) Marshall Elam et al.   CURRENT OPINION IN LIPIDOLOGY

RETRACTED: Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients by Lipid and Nonlipid Biomarkers

(2010) Benoit J. Arsenault et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

(2010) Paul M Ridker et al.   LANCET

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome

(2009) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes

(2009) Kausik K. Ray et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Association between dyslipidemia and vascular events in patients treated with statins: Report from the UK General Practice Research Database

(2009) Vasilisa Sazonov et al.   ATHEROSCLEROSIS

Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis

(2009) Eric Bruckert et al.   ATHEROSCLEROSIS

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)

(2009) PAUL M. RIDKER   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

(2009) Paul M Ridker et al.   LANCET

After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: Implications for Fenofibrate

(2008) Frank M. Sacks   AMERICAN JOURNAL OF CARDIOLOGY

Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity

(2008) Menno Vergeer et al.   CIRCULATION

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial

(2008) Michael Miller et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis

(2008)   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?

(2007) Philip J. Barter et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY